M-Vax + cyclophosphamide + bacillus Calmette-Guérin + interleukin-2

This is a **combination immunotherapeutic regimen** consisting of four components: - **M-Vax**: an autologous, dinitrophenyl (DNP)-hapten-modified tumor cell vaccine, developed primarily for melanoma. M-Vax is designed to stimulate an immune response against the patient's own tumor cells by rendering them more immunogenic. - **Cyclophosphamide**: a small molecule alkylating agent used as a chemotherapeutic and immunomodulating agent. It is utilized here for its ability to modulate the immune response, often to diminish regulatory T cell function and enhance vaccine efficacy[2][4][6][8]. - **Bacillus Calmette-Guérin (BCG)**: an attenuated live vaccine strain of Mycobacterium bovis, used for its non-specific immune-stimulating properties and as an immunotherapeutic adjuvant, particularly in vaccines like M-Vax[3]. - **Interleukin-2 (IL-2)**: a cytokine therapy employed to stimulate T cell proliferation and activation, commonly used to boost immune responses in cancer immunotherapy. The combination aims to maximally enhance anti-tumor immunity by combining direct tumor antigen vaccination (M-Vax), non-specific immune stimulation (BCG, IL-2), and immune environment modulation (cyclophosphamide). Principal indication is for melanoma, particularly in adjuvant or metastatic settings, though broad clinical application for other cancers is under study. M-Vax has been developed by **AVAX Technologies**[3][5].